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1. Abstract
Background and aims: Myeloid related protein 8/14 (MRP 8/14) is constitutively 
expressed in human neutrophils and monocytes and is secreted upon activation. In the 
acute coronary syndrome (ACS) MRP 8/14 is elevated at the site of the coronary 
occlusion and high levels have been associated with an increased risk of subsequent 
coronary events (CE) such as unstable angina (UA) or myocardial infarction (MI).
Our aim was to examine the value of MRP 8/14 as a cardiovascular (CV) risk predictor 
in a population of older survivors of ACS.
Methods: We measured MRP 8/14 levels in 119 elderly survivors of ACS in plasma 
samples collected at the acute event and at 6 week follow-up. The median age of the 
population was 79 years and 35% were female. The correlation between MRP 8/14 and 
the incidence of CE, stroke and all-cause mortality over a median follow-up period of 1.8 
years (2.7 for mortality) was studied using Cox regression models corrected for age and 
sex (Model A); age, sex and traditional CV risk factors [hypertension, smoking, body 
mass index (BMI), diabetes mellitus, high density lipoprotein (HDL) and low density 
lipoprotein (LDL)] (Model B) and all of the above plus c-reactive protein (CRP) (Model 
C).
Results: We found that MRP 8/14 at 6 weeks after the acute event and the difference 
between the values at 6 weeks follow-up and at the acute event, but not values at the 
acute event were associated with the risk of new CE.
Conclusion: MRP 8/14 may prove to be a useful follow-up biomarker to assess 
prognosis in ACS survivors.
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2. Populärvetenskaplig sammanfattning
Hjärtinfarkt är en av de vanligaste dödsorsakerna i världen och beror vanligtvis på att 
ett åderförkalkningsplack i hjärtats blodkärl brister. Placket består av en ansamling av 
fett, skumceller och rester av döda celler som ligger under ett lager av bindväv i 
kärlväggen. När placket brister aktiveras blodets koagulationssystem, då kärlväggen ej
längre är intakt. Blodet levrar sig inuti kärlet och bildar en blodpropp, en så kallad tromb. 
Tromben täpper till blodflödet, och orsakar syrebrist i det område kärlet försörjer vilket 
kan leda till att hjärtmuskelceller dör.
Man har på senare år funnit att immunförsvarets celler, de vita blodkropparna, har en 
viktig roll både vid uppkomsten av åderförkalkning och i processerna som leder till att ett 
plack försvagas så att det riskerar att brista. MRP 8/14 är ett protein som finns i vissa 
typer av vita blodkroppar som kallas neutrofiler och monocyter. Man har upptäckt att 
MRP 8/14 är förhöjt lokalt vid platsen för tromben vid en hjärtinfarkt och att höga nivåer
i blodet kan höja risken för att man skall få ytterligare en hjärtinfarkt i ett senare skede. 
Ingen av forskningen på MRP 8/14 som vi kunnat ta del av är gjord på äldre människor 
över 75 år, vilka utgör en stor del av alla som får hjärtinfarkt. I vår studie mätte vi 
nivåerna av MRP 8/14 på 119 personer över 75 år som haft en plackruptur i hjärtats kärl, 
i prover tagna strax efter att de kom till sjukhuset och vid ett återbesök efter sex veckor. 
Vi fann att förhöjda värden av MRP 8/14 vid det akuta insjuknandet inte i sig indikerade 
någon ökad risk för att åter drabbas. Däremot personer med förhöjda värden av MRP
8/14 vid återbesöket sex veckor efter insjuknandet och de som hade ökat i värde vid 
återbesöket jämfört med det akuta insjuknandet hade förhöjd risk för nya plackrupturer. 
MRP 8/14 skulle således kunna tänkas fungera som ett hjälpmedel för läkare att bedöma 
risken för att en patient skall återinsjukna i hjärtsjukdom.
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3. Introduction
3.1 MPR 8/14
The myeloid related proteins (MRP) 8 and 14 are members of the S100-protein family 
and are also titled S100A8 and S100A9 as well as calgranulin A and calgranulin B1. MRP
8 and 14 are mainly secreted as the heterodimer MRP 8/14. MRP 8/14 is expressed in 
cells of myeloid origin, such as neutrophils and monocytes. MRP 8/14 expression is 
markedly downregulated when monocytes differentiate into macrophages2. MRP 8/14 is 
an endogenous activator of toll like receptor 4 (TLR4) and the receptor for advanced 
glycation endproducts (RAGE). The intracellular function of MRP 8/14 is not fully 
mapped but its calcium dependent interactions with cytoskeletal components are 
established3. MRP 8/14 is released into the extracellular space via active secretion 
through a not yet elucidated route, as well as from necrotic cells after tissue damage1. 
Toll-like receptors (TLRs) play important roles in the innate immune responses and 
function as rapid pathogen sensors. Carriership of certain subtypes of TLR4 allele in 
combination with a subtype of its co-receptor CD14 is an independent predictor of 
atherosclerotic disease4. RAGE is an activator of signaling mechanisms that cause cell 
stress. RAGE is highly expressed in human atherosclerotic plaques5 and studies suggest
that RAGE expression in macrophages, smooth muscle cells (SMC) and endothelial cells 
contributes to the pathogenesis of atherosclerosis6.
MRP 8/14 stimulates recruitment and activation of neutrophils and monocytes and
plays a pivotal role as innate immune amplifier in various autoimmune and inflammatory 
diseases, such as rheumatoid arthritis, juvenile idiopathic artritis, inflammatory bowel 
disease, psoriasis, vasculitis, sepsis, cancer and transplant rejection. MRP 8/14 levels are 
increased in these patients and are currently used as inflammatory biomarkers for disease 
severity and progression1, 7-10.
3.2 Atherosclerosis
3.2.1 Atherogenesis- Fatty streak
The atheroma or athersosclerotic lesion is an asymmetric focal thickening of the tunica 
intima of the arterial wall. The precursor to the atheroma is the fatty streak, characterized
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by the accumulation of lipid-loaded macrophages and a small amount of T cells under the 
endothelium. The fatty streak does not cause symptoms, can evolve to an atheroma or 
revert and disappear11. Local shear stress and hyperlipidemia enable LDL to infiltrate and 
accumulate in the intima12. The LDL particles are then liable to oxidative modification. 
The oxidized LDL (oxLDL) is recognized as non-self by the immune system, which will 
be activated in order to remove it. The oxLDL and compounds thereof activate
endothelial cells to express adhesion molecules and chemokines. This causes the 
migration of monocytes into the intima13. In the intima monocytes differentiate into 
macrophages and upregulate scavenger receptors, which enables them to phagocyte 
oxLDL14. The cholesterol that cannot be utilized from the macrophages accumulates in 
cytosolic droplets. This causes an exhaustion of the macrophage and transforms it into a 
foam cell15.
Hyperlipidemia also stimulates granulopoesis in the bone marrow, leading to 
neutrophilia. Neutrophils have been detected in human atheroma and the quantity of 
neutrophils in the blood is correlated to the amount of atherosclerosis12, 16.Recent studies 
suggest that neutrophils are recruited early into the vessel wall and that they send out 
inflammatory signals that trigger the recruitment of monocytes17. Ox-LDL may induce 
transmigration and degranulation of neutrophils. Neutrophils are short lived cells that 
quickly become apoptotic and send out “find me” and “eat me” signals that attract 
macrophages for scavenging17. Thus neutrophils might have a key role in the initiation 
and development of atherosclerosis. MRP 8/14 is abundantly found inside the
neutrophils, constituting approximately 40% of all cytosolic proteins2. Extracellular MRP
8/14 promotes phagocytosis and has proinflamatory effects on neutrophils and 
monocytes/macrophages, probably via activation of TLR4 and RAGE18, 19. Intracellular 
MRP 8/14 promotes adhesion and migration of neutrophils and macrophages through 
calcium and microtubule regulation3.
3.2.2 Atherogenesis – The advanced fibrotic lesion
The ubiquitously present pathogen-like molecular patterns bind to TLRs on 
macrophages, triggering a signal cascade leading to cell activation20. Activated 
macrophages produce inflammatory cytokines, chemokines, proteases and cytotoxic
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oxygen radical molecules. This in turn can causes tissue damage and further recruitment 
of inflammatory cells such as T lymphocytes12.
T helper type 1 lymphocytes (Th1) and their signature cytokines interferon-γ (IFN- γ), 
interleukin-12 (IL-12) and interleukin-18 (IL-18) are present in the human plaque and are 
thought to contribute to the atherosclerotic process21. Experiments in mice have shown 
that blocking the generation of Th1 cells as well as blocking the production or signaling 
ability of IFN- γ decreases plaque burden and that elevated levels of IFN- γ or IL-12 lead 
to increased atherosclerosis12.
The activated macrophages and endothelial cells secrete growth factors that cause the 
recruitment and proliferation of SMC from the tunica media of the arterial wall. These 
cells secrete matrix protein, including interstitial forms of collagen. In time, the SMC 
and their secreted fibers form a fibrous cap that covers the foam cells and separates the 
atheroma from the lumen12. Under the fibrotic cap the foam cells are trapped and 
gradually become apoptotic and die, releasing their inner lipids into the extracellular 
space. This process gradually leads to the formation of the necrotic core, which is mainly 
made up by cell debris and extracellular lipids.
3.2.2 Atherogenesis – plaque stability and rupture
As the plaque grows it can occlude the arterial lumen, lowering the blood flow to such 
an extent that it causes symptoms from its irrigated territory. This is the case in stable 
arterial disease such as angina pectoris or claudicatio intermittens. It is known that tight 
coronary stenoses are often stable and do not precipitate an acute MI22.
In histological studies it has been shown that the stable plaque usually has a relatively 
thick fibrous cap and a small lipid core. The rupture-prone plaque, termed vulnerable 
plaque, has a large lipid core and a thin fibrous cap23 and is often characterized by an 
accumulation of activated macrophages and T cells into the rupture-prone shoulder 
region of the lesion24. The integrity of the fibrous cap can be compromised by several 
inflammatory processes. Macrophages, activated by Th1 cytokines and other factors, can 
release matrix metalloproteinases (MMPs) that degrade the collagen within the cap25. 
Collagen production in the SMCs of the plaque can also be inhibited by Th1 cells26. 
Smaller studies of human atheroma show that vulnerable plaques are rich in
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inflammatory cell that all show a robust expression of MRP 8/14 and that rupture prone 
lesions have a higher percentage of MRP 8/14 positive macrophages than stable ones27.
3.3 Coronary Artery Disease
When atherosclerotic lesions develop in the coronary arteries they give rise to coronary 
artery disease (CAD). Worldwide more than 7 million people die from ischemic heart 
disease each year.28 CAD can be divided into stable and unstable disease. Stable CAD 
develops when a stable atherosclerotic lesion has grown to such extent that it restricts the 
blood flow to the myocardium. In a situation with increased demand this restricted blood 
flow will not suffice and a relative ischemia will develop, causing discomfort and pain 
(angina pectoris).
3.3.1 Acute Coronary Syndrome
The unstable CAD or the ACS is commonly caused by a thrombus that forms in a 
coronary artery, following the rupture of an atherosclerotic plaque29.
Based on the ECG aspect and the release of markers of myocardial necrosis, ACS can 
be divided in to the subcategories: ST-elevation myocardial infarction (STEMI), non-ST-
elevation myocardial infarction (non-STEMI) and UA29, where the coronary oclusion 
causes an relative ischemia leading to discomfort but not myocardial necrosis.
The serum levels of MRP 8/14 in ACS patients have been shown to be elevated 
compared to controls with stable CAD30 and were shown to peak between days 3-5 after 
the onset of symptoms 31.
Comparison of MRP 8/14 levels in samples taken from the site of coronary occlusion 
with samples from the femoral artery showed that MRP 8/14 is significantly elevated at 
the site of the thrombi30. It has been shown that inflammation plays a significant role in 
the reparation of the injured heart32 and that the inflammatory process can continue 
beyond the initial repair phase, spreading from the infarcted area into the surrounding 
myocardium and playing a role in the harmful remodeling leading to chronic heart
failure33. In mice, sustained MRP 8/14 activation critically contributes to the development 
of post ischemic heart failure via activation of RAGE34. Pathological studies in humans 
showed a significantly larger area stained positive for MRP 8/14 in an infarcted 
myocardium compared to controls. Initially, 6h to 2 days after the onset of MI, the vast
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majority of MRP 8/14 positive cells in this area were neutrophils, but shifted towards 
macrophage domination in the sub acute phase, day 7-9 after MI31.
Roughly 33% of all ACS episodes occur in patients above the age of 75 years and 
account for approximately 60% of the mortality cases due to ACS35. The elderly represent 
a special challenge in the diagnosis of ACS as well as in managing the disease. They 
present more often with atypical symptoms and many have abnormal resting ECG36, 37.
The risk for adverse events is also higher in elderly ACS patients. Complication rates for 
reperfusion, anticoagulation and antiplatelet therapies are higher than that of younger 
patients, but at the same time the elderly have a higher chance to benefit from these 
therapies38, 39. Still elderly patients are at greater risk of getting suboptimal treatment for 
ACS and there is a need for developing improved methods for risk stratification40.
3.4 Biomarkers for cardiovascular risk and secondary prevention
It has been shown that smoking and dyslipidemia are associated with approximately
60% of the risk to develop an acute MI. Taken together with hypertension, diabetes, 
abdominal obesity, psychosocial factors, low consumption of fruits and vegetables and 
reduced regular physical activity, the above mentioned factors account for more than
90% of the CV risk 41.
There is an abundance of biomarkers of less importance than the above mentioned, but 
with the potential to identify patients with a more specified risk. Some of these are 
readily available and well linked to CV disease, such as high sensitivity-CRP (hsCRP), 
homocystein, natriuretic peptides and neutrophil count42-44. Other inflammatory 
biomarkers which have been thought to signal the presence of unstable plaques and 
plaque rupture, such as MMP-9, myeloperoxidase, vascular cell adhesion molecule 
(VCAM) are less available and lack reliable evidence42. A meta analysis assessing the 
relation between early CRP levels after ACS and the risk of adverse outcomes has found 
a moderately dose-dependent positive association between early blood CRP values and 
long term risk of recurrent CV events or death in patients with ACS (CRP >10mg/L is 
associated with 2.18-fold higher risk)45.
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3.4.1 MRP 8/14 as a biomarker in primary and secondary prevention
In a primary prevention population study on healthy postmenopausal women, elevated 
MRP 8/14 levels (>3.36 mg/L) at baseline predicted a relative risk of 2.3 for a CV event 
in the next 2.9 years, when controlling for both traditional risk factors and CRP46.
A later study on patients presenting with chest pain showed that high concentrations of 
MRP 8/14 measured at the acute event were associated with increased risk for CV 
death47. MRP 8/14 was also associated with all cause mortality but when controlling for 
traditional clinical risk factors and CRP in a Cox proportional hazard analysis MRP 8/14 
lost significance and CRP emerged as a far stronger predictor47.
3.5 Objective
Our aim was to examine the value of MRP 8/14 as a CV risk predictor in a population 
of older survivors of ACS (MI and UA).
4. Methods
4.1 Study population
The study population was part of the “Elderly project”, a prospective study including 
patients being treated for ACS at the Cardiology Clinic SUS Malmö from 2008 and 
onwards. All participants provided informed consent and the study was approved by the 
ethical committee at Lund University, Sweden.
Participants in this study were chosen on the criteria that they were above 75 years of 
age when they were enrolled in the study and that they participated in the 6 week follow-
up.
4.2 Blood sampling
Samples of venous blood were obtained from all patients in tubes containing EDTA, at 
inclusion on the day after the acute event and at the 6 week follow-up. Plasma was 
extracted from the samples and stored at -80oC. Plasma levels of MRP 8/14 were
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measured using an enzyme-linked immunoassay (ELISA) (BMA Biomedicals, Augst
Swizerland,).
4.3 Clinical data
Information on the presence of CV risk factors was gathered from the Swedeheart 
national register. For patients that had not been registered in the Swedeheart national 
register, medical information was gathered from local journals. Biochemical laboratory 
measurement data at the time of the acute event and at follow-up were gathered from the 
journals of study participants.
Measurement of the marker for myocardium necrosis troponin was changed from the I 
subtype to the T subtype at SUS Malmö in may 2011. To enable the use of these separate 
markers as a measurement of myocardial necrosis in our analysis, the recorded values 
were divided by the maximum value of their individual normal range, thus forming a 
troponin quota that was included in our statistical analysis. Blood pressure was measured 
with a mercury-column sphygmomanometer after resting for 10 min in the supine 
position. Hypertension was defined as systolic blood pressure (SBP) 140 mmHg, 
diastolic blood pressure (DBP) 90 mmHg or use of antihypertensive medication. 
Diabetes mellitus was defined as a fasting whole-blood glucose level greater than 6.0 
mmol/L, a self-reported physician diagnosis of diabetes or use of antidiabetic medication.
4.4 Study end-points
The study end-points were CE (MI, UA or CV death), stroke, heart failure and all-cause 
mortality during follow-up. Events were identified through linkage of the 10-digit 
personal identification number of each Swedish citizen with the Swedish hospital 
discharge register and the Swedish Cause of Death Register. CE was defined as main 
diagnose being MI ICD10 codes I21 and I22 or unstable or undefined angina pectoris 
codes I200, I208 or I209. Stroke was defined as codes I60-I64, heart failure as I50.
Follow-up for outcomes from the Swedish hospital discharge register continued up until 1
January 2012, outcomes from the Swedish Cause of Death Register continued until 1
November 2012.
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4.5 Statistical analysis
SPSS software (version 21; SPSS Inc, Chicago, IL, USA) was used for all statistical 
calculations. The degree of co-variation between MRP 8/14 levels and other CV risk 
factors was studied in a bivariate Spearman correlation including the factors shown in 
Table 2.  To assess the importance of increasing, respectively decreasing MRP values at 
the 6 weeks follow-up compared to the acute event, a Pearson chi-square analysis was 
performed (Table 3). We performed a multivariate Cox regression (time to event) 
analysis to assess whether increasing tertiles of MRP 8/14 were related to increased risk 
of coronary events, stroke or all-cause mortality. Separate analyses were performed for 
inclusion and follow-up values as well as for the differential between the two (ΔMRP
8/14). We used three different models adjusted for: age and sex (Model A), age, sex, 
hypertension, smoking, BMI, diabetes mellitus, HDL and LDL (Model B) and age, sex, 
hypertension, smoking, BMI, diabetes mellitus, HDL, LDL and CRP (Model C). The 
values for MRP 8/14 and CRP were logarithmically transformed before being included in 
the analysis as continuous variables. Data were expressed as hazard ratio (HR) and 95% 
confidence interval (CI). A two sided value of P< 0,05 was considered statistically 
significant. Kaplan Meyer curves were rendered to illustrate the association between
MRP 8/14 and the risk for CE.
5. Results
5.1 Characteristics of the study group
Of the 572 patients included in the “Elderly project” at the time, 119 fulfilled the 
inclusion criteria. Follow-up data for coronary events, stroke, heart failure and CV death 
were available for 113 subjects, and for all-cause mortality for 119 individuals. The 
median age of the participants was 79 years and 35% were women (Table 1). At the time 
of inclusion 23% of the patients had diabetes, 65% had hypertension and 8% were active 
smokers. During a median follow-up of 1.8 years (interquartile range (IQR), 0.7-2.7), 35 
individuals suffered another CE, 8 were diagnosed with stroke, 14 with heart failure (data 
not shown) and 6 died of CVD. During a median follow-up of 2.7 years (IQR 1.5-3.6) we 
recorded a total of 16 deaths (Table 1).
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5.2 MRP 8/14 and the presence of traditional risk factors for CVD
In a Spearman correlation analysis (Table 2), MRP 8/14 values at the acute event and at
6 weeks follow-up were both significantly correlated with CRP. The MRP 8/14 
concentration at the acute event was strongly correlated with the white blood cell count 
(WBC) (R=0.342 p<0.000 The 6 week follow-up MRP 8/14 similarly correlated with 
follow-up WBC (R= 0.259 p= 0.005).
At inclusion there was a strong correlation between MRP 8/14 and hypertension (R=
0.31 p=0.001), but this correlation lost power at follow-up (R=0.18 p=0.052), becoming 
borderline significant. The troponin quota correlated with MRP 8/14 at inclusion (R=
0.254 p=0.006), but not with the MRP 8/14 concentration at 6 week follow-up. No other 
significant correlations could be shown between MRP 8/4 and the traditional risk factors.
5.3 MRP 8/14 and CV risk
A chi-square analysis (Table 3) investigating if increase or decrease of MRP 8/14
values from the acute ACS event to the 6 week follow-up were connected to morbidity or 
mortality did not yield any significant results. Nevertheless, a trend could be recognized, 
with a higher probability for CE (P=0.081) and CV death (P= 0.094) for patients with 
increasing MRP 8/14 values.
The study participants were categorized according to tertiles of plasma MRP 8/14 
concentration at inclusion and at the 6 week follow-up as well as of the differential 
between the two ( MRP). In Cox regression models adjusted for age and sex (Model A); 
age, sex and traditional risk factors (Model B) and age, sex, traditional risk factors and 
CRP (Model C) the inclusion values did not account for an increased risk in any of the 
considered endpoints (Table 4.1). The 6 week follow-up values (table 4.2) showed an 
association with the risk of a CE, association that remained significant through the three 
different analysis models. When controlling for age, sex, traditional risk factors and CRP 
(Model C), the 3rd tertile yielded a HR of 4.09 (1.29- 12.96) when compared to the 1st 
tertile. No significant associations could be found for stroke and all cause mortality. The 
Cox analysis of the ΔMRP 8/14 (table 4.3) also rendered significant results for CE, 2.88 
(1.00- 8.32) for the 3rd tertile in Model C. To visualize the incidence of CE during the
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follow-up period by MRP 8/14 tertiles, three Kaplan-Meyer graphs were rendered (Figure
1).
6. Discussion
In recent years an abundance of novel inflammatory biomarkers for prediction of CVD 
have emerged42. Of these, MRP 8/14 has shown promising results in a number of 
studies30, 31, 46, 48. MRP 8/14 correlates strongly with leukocyte count, implying a 
connection to the systemic inflammatory activity. In a previous study on 664 individuals 
from the Malmö Diet and Cancer (MDC) cohort we found that MRP 8/14 concentrations 
correlate strongly with the numbers of circulating white blood cells and neutrophils, but 
not circulating monocytes or monocyte sub-population (unpublished results)., Increased
neutrophil counts have been associated with the incidence of CE in a healthy population43,
44. Since MRP 8/14 correlates to neutrophil counts and both high neutrophil counts and 
high MRP 8/14 are associated with increased risk for CE, MRP 8/14 might be a marker 
for neutrophil activation, leading to plaque destabilization and CE. The strong correlation 
between MRP 8/14 and the leukocyte counts might be a sign the increased neutrophil 
activation and MRP 8/14 secretion during the acute phase of the ACS31.
The strong and significant correlation between MRP 8/14 at the acute event and the 
troponin quota implies that the release of MRP 8/14 is related to the grade of 
myocardium necrosis in the ACS. It has been shown that MRP 8/14-positive neutrophils 
and monocytes infiltrate the infarcted myocardium31 and that the blood levels of MRP
8/14 are elevated at the site of the occlusion compared to the systemic circulation30. 
Furthermore, MRP 8/14 has an active role in the thrombus responsible for the ACS where 
they stimulate monocytes via TLR449 and contribute to platelet activation46, 50. Puzzling is 
the correlation between hypertension and MRP 8/14, which has not been mentioned in
any previous study. Rather than reflecting on a physiological mechanism this might be a 
result of the relatively small size of the study and to the broad definition of hypertension 
that we have used.
To our knowledge, no studies have been performed on the value of MRP 8/14 as a 
biomarker in an elderly population. We set out to elucidate the potential of MRP 8/14 as
a predictor of recurrent CV events in a population of ACS survivors over 75 years of age. 
We found that MRP 8/14 sampled 6 weeks after the acute event was an independent
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predictor of major adverse CE, were patients with MRP 8/14 values within the 3rd tertile 
ran a 4 times higher risk to develop subsequent CE compared to the first tertile. This is in 
line with the results of Morrow et al.48 comparing ACS patients that suffered a recurrent 
ACS in the first month after the initial episode with those that did not have a second 
episode during the same period. MRP 8/14 were measured 30 days after the initial event, 
and was found to be significantly elevated in the group with recurrent ACS.  Patients with 
a MRP 8/14 of >11mg/L had relative odds of 2.0 of CV death or another MI, even when 
controlling for both clinical variables/traditional risk factors and hsCRP. Notable 
similarities between these studies are the predictive value of MRP 8/14 in a time well
after the acute event (30 days/6 weeks) and an association with increased risk that 
withstands control for traditional risk factors and CRP.
Patients with increasing MRP 8/14 at the 6 weeks follow-up had a higher risk for CE 
and CV death. Our interpretation of these results is that sustained or amplified neutrophil 
activation during the period following ACS is a potential trigger for subsequent CV 
events.
A previous study on patients presenting with chest pain has shown that the 
concentration of MRP 8/14 at the acute event has predictive value for the risk of CV 
death 47, 48. We could not show any predictive value of MRP 8/14 measured at the acute 
event for either CV death, all cause mortality, CE or stroke. This could be due to
differences in sampling since the samples in our study were collected not at admittance to 
the hospital but at inclusion on the day after admittance. Another reason for discrepancy
in results could be the difference in the characteristics of the study populations. Our 
population of elderly ACS survivors (median age 79 years) that were healthy enough to 
attend the 6 week follow-up visit is significantly older than the population included in 
previous studies (median age 61 and 64 years) and might also differ in other risk factors.
Limitations to this study merit consideration. Firstly, our results regarding CV death 
and stroke have to be interpreted with due caution due to the low numbers of events 
recorded during follow-up. The study excluded ACS sufferers that could not attend the 6 
week follow-up, a group which could be assumed to be in lesser health than the study 
population. Since MRP 8/14 is elevated in a row of oncological and immunological 
diseases1, 7, these diseases could vey well have a higher prevalence in the excluded group.
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In conclusion, the results of our prospective study suggest that MRP 8/14 measured 
during follow-up in elderly ACS survivors is able to predict the risk of a new CE 
independently of age, sex, traditional risk factors and CRP. If these results can be 
confirmed in larger studies, MRP 8/14 might be employed as a useful inflammatory 
biomarker for guiding risk stratification in secondary prevention of acute CE.
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8. Tables
Table 1. Baseline characteristics of the study population
Characteristic Population Non-Cases Coronary
Event
Stroke Cardiovascular
Death
All Cause
Death
Number of participants 119 74 35 8 6 16
Age, median ( interquartile range )
years
79 (77-91) 80 (77-84) 79 (75-83) 80 (78-83) 84 (83-86) 83 (80-85)
Female gender (%) 41 (35) 26 (35) 12 (34) 5 (63) 2 (33) 4 (25)
BMI (SD), kg/m2 26.5 (4) 26.8 (4.4) 26.3 (3.5) 26.2 (3.7) 25.8 (4.0) 25.6 (3.6)
Diabetes (%) 27 (23) 18 (24) 8 (23) 0 (0) 1 (17) 2 (13)
Current Smoking (%) 9 (8) 3 (4) 2 (6) 1 (13) 0(0) 3 (19)
Hypertension (%) 67 (65) 44 (60) 26 (74) 6 (75) 6 (100) 13 (82)
Blood pressure, mean (SD), mm Hg
Systolic 150 (25) 153 (23) 142 (28) 180 (*) 170 (36) 150 (38)
Diastolic 80 (13) 82 (12) 73 (12) 80 (*) 78 (3) 80 (11)
Laboratory values
CRP at acute event (IQR), mg/L 3 (>2-9) 3.8 (2.0-13.8) 3 (>2-8) 2.5 (>2-6.8) 3 (2.0-3.5) 3 (>2-6.9)
CRP at 6 weeks follow-up
median (IQR), mg/L, mg/L
3 (1-9) 3.7 (1.1- 6.55) 3 (1-7.4) 4.5 (1-9) 7 (1-36.3) 1 (1-8.4)
MRP 8/14 at acute event, median
(IQR), mg/L
2.56
(2.01-3.56)
2.35 (1.96-3.75) 2.65 (2.13-3.48) 2.54 (1.80-3.27) 2.58 (2.32- 3.20) 2.58 (2.18-
3.33)
MRP 8/14 at 6 weeks follow-up median
(IQR), mg/L
2.16
(1.66-3.09)
2.46 (1.56- 2.83) 2.63 (2.06-3.39) 2.64 (2.13- 3.30) 3.21 (2.04-4.45) 2.39 (1.89-
3.55)
Leucocytes at the acute event (SD), x
10 9 /L
9.2 (3.3) 9.2 (3.4) 8.8 (3.4) 7.9 (1.9) 9.8 (5.3) 10.9 (4.2)
Leucocytes at 6 week follow-up(SD), x
10 9 /L
7.2 (2.0) 7.2 (1.9) 7.1 (2.2) 7.2 (2.3) 7.3 (2.7) 7.7 (2.4)
HDL-C at the acute event (SD), mmol/L 1.2 (0.4) 1.2 (0.4) 1.2 (0.3) 1.4 (0.4) 1.1 (0.2) 1.1 (0.3)
LDL-C at the acute event (SD), mmol/L 3.0 (1.0) 3.2 (1.2) 2.8 (0.9) 3.2 (0.6) 2.7 (0.8) 2.9 (0.94)
TG at the acute event(SD), mmol/L 1.1 (0.5) 1.1 (0.6) 1.0 (0.3) 0.9 (0.29) 0.97 (0.42) 1.1 (0.31)
BMI, body mass index; CRP, C-reactive protein; MRP 8/14 Myeloid Related Protein 8/14; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, Triglycerides. *BP info only available for 1 patient in the stroke group.
Table 2. Associations between MRP 8/14 levels, CV risk factors and other inflammatory biomarkers
MRP 8/14
at the acute event
MRP 8/14
at 6 weeks follow up
Correlation 
coefficient
P* Correlation
Coefficient
P*
Age 0.082 0.38 -0.009 0.92
Gender -0.022 0.82 -0.019 0.84
BMI 0.077 0.41 0.029 0.76
Diabetes 0.166 0.07 0.040 0.67
Smoking 0.105 0.26 0.018 0.85
Hypertension 0.311 0.00 0.180 0.05
Blood pressure, mm Hg
Systolic 0.112 0.34 -0.127 0.28
Diastolic 0.057 0.63 -0.211 0.07
Laboratory values
CRP 0.432 0.00 0.481 0.00
Leucocytes 0.342 0.00 0.259 0.01
HDL-C -0.102 0.3 0.022 0.82
LDL-C -0.083 0.41 0.015 0.88
TG 0.171 0.08 0.000 0.98
Troponin quota# 0.254 0.01 0.123 0.18
* Bivariate Spearman correlation test. # Recorded values of troponin I and troponin T, divided by the maximum value of their
individual normal range.
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Table 3. MRP 8/14 development following the acute event and the risk of subsequent CVdisease
Increasing (n=39) Decreasing (n=78) P*
Coronary event, (%) 15 (38.5) 18 (23.1) 0.081
Stroke, (%) 4 (10.3) 4 (5.1) 0.30
Cardiovascular death (%) 4 (10.3) 2 (2.6) 0.094
All-cause death (%) 7 (17.9) 9 (11.5) 0.341
Heart failure (%) 3 (7.7) 10 (12.8) 0.40
* Pearson Chi-square test.
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Table 4.1 MRP 8/14 at the acute event and the risk for subsequent CVD and all-cause mortality
MRP 8/14 tertile
Hazard ratio (95% CI)
Linear trend
Event T2 vs. T1 T3 vs. T1 Hazard ratio (95% CI) P
Coronary event
A 1.08 (0.46- 2.55) 1.15 (0.501-2.64) 1.07 (0.71 – 1.625) 0.74
B 1.27 (0.49- 3.29) 0.75 (0.28-2.03) 0.86 (0.54 – 1.38) 0.54
C 1.50 (0.54 – 4.2) 1.16 (0.37 – 3.6) 1.09 (0.63 – 1.87) 0.76
Stroke
A 1.96 (0.35-10.83) 0.80 (0.11-5.85) 0.90 (0.38- 2.09) 0.80
B 3.15 (0.43- 23.4) 0.84 (0.09-7.56) 0.89 (0.36- 2.20) 0.80
C 3.42 (0.43 -27.48) 0.75 (0.06- 9.52) 0.92 (0.315-2.70) 0.88
All cause mortality
A 3.38 (0.93- 12.33) 0.92 (0.22-3.8) 0.94 (0.53 -1.68) 0.84
B 4.05 (0.71-23.18) 0.59 (0.81-4.34) 0.72 (0.32-1.60) 0.46
C 15.11 (1.5 – 152.27) 0.69 (0.06-7.64) 0.84 (0.34-2.24) 0.78
Model A adjusted for age and sex.
Model B adjusted for age, sex, hypertension, smoking, BMI, diabetes, HDL and LDL.
Model C adjusted for age, sex, hypertension, smoking, BMI, diabetes, HDL, LDL and CRP.
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Table 4.2 MRP 8/14 at 6 week follow-up and and the risk for subsequent CVD and all-cause mortality..
MRP 8/14 tertiles
Hazard ratio (95% CI)
Linear trend
Event T2 vs. T1 T3 vs. T1 Hazard ratio (95% CI) P
Coronary Event
A 2.26 (0.78-6.5) 3.90 (1.43-10.66) 1.91 (1.21- 3.03) 0.005
B 2.18 (0.68- 6.98) 3.41 (1.20-9.70) 1.80 (1.10-2.92) 0.018
C 2.38 (0.72- 7.93) 4.09 (1.29- 12.96) 1.97 (1.14-3.37) 0.014
Stroke
A 2.31 (0.24- 22.56) 3.99 (0.43-36.73) 1.92 (0.72- 5.17) 0.19
B 0.85 (0.54-13.45) 2.74 (0.28-26.72) 1.98 (0.63- 6.17) 0.24
C 0.87 (0.05-15.90) 2.83 (0.23-34.52) 2.05 (0.61- 6.86) 0.24
All cause Mortality
A 1.35 (0.38- 4.84) 2.47 (0.66- 9.16) 1.58 (0.81- 3.09) 0.18
B 0.98 (0.23- 4.18) 1.51 (0.35- 6.65) 1.24 (0.58- 2.65) 0.58
C 1.04 (0.23- 4.77) 1.66 (0.311-8.93) 1.31 (0.56- 3.08) 0.54
Model A adjusted for age and sex.
Model B adjusted for age, sex, hypertension, smoking, BMI, diabetes, HDL and LDL. 
Model C adjusted for age, sex, hypertension, smoking, BMI, diabetes, HDL, LDL and CRP
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Table 4.3  ΔMRP 8/14* and and the risk for subsequent CVD and all-cause mortality.
MRP 8/14 tertile (T) 
Hazard ratio (95% CI)
Linear trend
Event T2 vs. T1 T3 vs. T1 Hazard ratio (95% CI) P
Coronary Event
A 1.63 (0.61- 4.33) 2.48 (0.99- 6.2) 1.56 (1.00-2.44) 0.046
B 1.84 (0.63- 5.39) 2.74 (0.99- 7.59) 1.64 (1.00- 2.67) 0.049
C 1.84 (0.62- 5.4) 2.88 (1.00- 8.32) 1.68 (1.00- 2.83) 0.049
Stroke
A 4.09 (0.39-42.69) 5.08 (0.55- 47.11) 1.95 (0.78-4.86) 0.151
B 3.33 (0.27- 41.40) 4.84 (0.49- 47.40) 1.99 (0.75- 5.28) 0.164
C 3.41 (0.27- 43.00) 5.02 (0.49- 51.94) 2.03 (0.74- 5.52) 0.167
All cause mortality
A 1.25 (0.29- 5.37) 2.98 (0.85-10.50) 1.77 (0.93-3.36) 0.082
B 1.78 (0.33-9.65) 3.67 (0.81- 16.64) 1.93 (0.91-4.08) 0.087
C 2.10 (0.36- 12.14) 5.20 (9.96-28.14) 2.30 (0.99- 5.32) 0.052
Model A adjusted for age and sex.
Model B adjusted for age, sex, hypertension, smoking, BMI, diabetes, HDL and LDL. 
Model C adjusted for age, sex, hypertension, smoking, BMI, diabetes, HDL, LDL and CRP.
*ΔMRP 8/14 is the differential between MRP 8/14 at the acute event and at 6 week follow-up.
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Figure 1. Kaplan-Meyer graphs depicting one minus coronary event free survival by MRP8/14 tertile
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